摘要
目的:探讨人脐静脉内皮细胞(HUVEC)疫苗与低剂量化疗药多西紫杉醇(DOC)联合能否产生协同抗乳腺癌转移作用。方法:BALB/c小鼠随机分成生理盐水组、HUVEC疫苗组、DOC组及HUVEC疫苗与DOC联用组(HUVEC-DOC)四组,尾静脉注射小鼠EMT-6乳腺癌细胞建立人工肺转移模型,评价不同治疗方案抗肿瘤转移作用。采用脾淋巴细胞增殖实验、细胞毒性T淋巴细胞杀伤实验及IFN-γ含量测定实验检测给药后各组小鼠细胞免疫应答水平。结果:相较于HUVEC疫苗及DOC单药组,HUVEC-DOC联合治疗组肺脏肿瘤转移灶数目明显减少(P<0.05);相较于各单药组,HUVEC-DOC组小鼠的脾淋巴细胞增殖能力和CTL杀伤能力均显著增强(P<0.05);ELISA检测小鼠脾淋巴细胞上清中IFN-γ实验结果显示联合治疗组INF-γ的含量明显高于其他三组(P<0.05)。结论:HUVEC疫苗与低剂量的DOC联用具有协同抗乳腺癌作用,该作用与增强的HUVEC特异性细胞免疫应答有关。
Objective:To investigate whether human umbilical vein endothelial cell(HUVEC)vaccine combined with low dose docetaxel(DOC)could play a synergistic role in anti-breast cancer.Methods:BALB/c mice were randomly divided into normal saline group,HUVEC vaccine group,DOC group,and HUVEC vaccine combined with DOC treatment group(HUVEC-DOC)group.An experimental metastasis model by tail vein injection of EMT-6 breast cancer cells was employed to evaluate the anti-metastatic efficiency of the HUVEC-DOC combination treatment regime.Lymphocyte proliferation assay,cytotoxic T lymphocytes and an indirect enzyme-linked immunosorbent assay(ELISA)for detecting IFN-γwere used to investigate cellular immune responses elicited by the combination treatment regime.Results:Compared with HUVEC and DOC single drug group,the number of lung metastasis in HUVEC-DOC combination treatment group was significantly decreased(P<0.05).In vitro analysis of splenocytes isolated from immunized mice revealed an induction of cytotoxic T lymphocytes(CTLs)with a lytic activity against activated endothelium.IFN-γin the serum of im-munized mice of the HUVEC-DOC combination treatment group was significantly higher than that in the other three groups(P<0.05).Conclusion:HUVEC vaccine with low dose of DOC could display synergistic anti-breast cancer effect.
作者
鲁美钰
仲维兰
董万法
姚庆收
司春枫
周玲
徐茂磊
LU Mei-Yu;ZHONG Wei-Lan;DONG Wan-Fa;YAO Qing-Shou;SI Chun-Feng;ZHOU Ling;XU Mao-Lei(The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine,School of Pharmacy,Binzhou Medical University,Yantai 264003,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2018年第3期367-370,375,共5页
Chinese Journal of Immunology
基金
国家自然科学基金(No.81541158)
山东省优秀中青年科学家科研奖励基金(No.BS2014YY051)
山东省自然科学基金(No.ZR2015PH002)
山东省高等学校科技计划(No.J15LM51
J15LE51)
关键词
人脐静脉内皮细胞
抗血管生成
乳腺癌
联合治疗
紫杉醇
Human umbilical vein endothelial cells
Anti-angiogenesis
Breast cancer
Combination therapy
Paclitaxel
